Cargando…
Considerations for vaccinating children against COVID-19
COVID-19 vaccines have been introduced in children and adolescents in many countries. However, high levels of community transmission and infection-derived immunity make the decision to introduce COVID-19 vaccination of children in countries yet to do so particularly challenging. For example, other v...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373744/ https://www.ncbi.nlm.nih.gov/pubmed/37487674 http://dx.doi.org/10.1136/bmjpo-2023-001964 |
_version_ | 1785078625514553344 |
---|---|
author | Hart, John D Ong, Darren Suryawijaya Chokephaibulkit, Kulkanya Ong-Lim, Anna T Vereti, Ilisapeci Crawford, Nigel W Russell, Fiona |
author_facet | Hart, John D Ong, Darren Suryawijaya Chokephaibulkit, Kulkanya Ong-Lim, Anna T Vereti, Ilisapeci Crawford, Nigel W Russell, Fiona |
author_sort | Hart, John D |
collection | PubMed |
description | COVID-19 vaccines have been introduced in children and adolescents in many countries. However, high levels of community transmission and infection-derived immunity make the decision to introduce COVID-19 vaccination of children in countries yet to do so particularly challenging. For example, other vaccine preventable diseases, including measles and polio, generally have far higher childhood morbidity and mortality in low-income and middle-income countries (LMICs) than COVID-19, and coverage with these vaccines has declined during the pandemic. Many countries are yet to introduce pneumococcal conjugate and rotavirus vaccines for children, which prevent common causes of childhood death, or human papillomavirus vaccine for adolescents. The Pfizer and Moderna COVID-19 vaccines that have been widely tested in children and adolescents had a positive risk-benefit profile at the time they were tested. However, the benefit is less compared with other life-saving vaccines in this age group, particularly in LMICs and settings with widespread infection-derived immunity. The resources required for rollout may also pose a considerable challenge in LMICs. In this paper, we describe COVID-19 in children, with a focus on LMICs, and summarise the published literature on safety, efficacy and effectiveness of COVID-19 vaccination in children and adolescents. We highlight the complexity of decision-making regarding COVID-19 vaccination of children now that most of this low-risk population benefit from infection-derived immunity. We emphasise that at-risk groups should be prioritised for COVID-19 vaccination; and that if COVID-19 vaccines are introduced for children, the opportunity should be taken to improve coverage of routine childhood vaccines and preventative healthcare. Additionally, we highlight the paucity of epidemiological data in LMICs, and that for future epidemics, measures need to be taken to ensure equitable access to safe and efficacious vaccines before exposure to infection. |
format | Online Article Text |
id | pubmed-10373744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-103737442023-07-28 Considerations for vaccinating children against COVID-19 Hart, John D Ong, Darren Suryawijaya Chokephaibulkit, Kulkanya Ong-Lim, Anna T Vereti, Ilisapeci Crawford, Nigel W Russell, Fiona BMJ Paediatr Open Review COVID-19 vaccines have been introduced in children and adolescents in many countries. However, high levels of community transmission and infection-derived immunity make the decision to introduce COVID-19 vaccination of children in countries yet to do so particularly challenging. For example, other vaccine preventable diseases, including measles and polio, generally have far higher childhood morbidity and mortality in low-income and middle-income countries (LMICs) than COVID-19, and coverage with these vaccines has declined during the pandemic. Many countries are yet to introduce pneumococcal conjugate and rotavirus vaccines for children, which prevent common causes of childhood death, or human papillomavirus vaccine for adolescents. The Pfizer and Moderna COVID-19 vaccines that have been widely tested in children and adolescents had a positive risk-benefit profile at the time they were tested. However, the benefit is less compared with other life-saving vaccines in this age group, particularly in LMICs and settings with widespread infection-derived immunity. The resources required for rollout may also pose a considerable challenge in LMICs. In this paper, we describe COVID-19 in children, with a focus on LMICs, and summarise the published literature on safety, efficacy and effectiveness of COVID-19 vaccination in children and adolescents. We highlight the complexity of decision-making regarding COVID-19 vaccination of children now that most of this low-risk population benefit from infection-derived immunity. We emphasise that at-risk groups should be prioritised for COVID-19 vaccination; and that if COVID-19 vaccines are introduced for children, the opportunity should be taken to improve coverage of routine childhood vaccines and preventative healthcare. Additionally, we highlight the paucity of epidemiological data in LMICs, and that for future epidemics, measures need to be taken to ensure equitable access to safe and efficacious vaccines before exposure to infection. BMJ Publishing Group 2023-07-24 /pmc/articles/PMC10373744/ /pubmed/37487674 http://dx.doi.org/10.1136/bmjpo-2023-001964 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Hart, John D Ong, Darren Suryawijaya Chokephaibulkit, Kulkanya Ong-Lim, Anna T Vereti, Ilisapeci Crawford, Nigel W Russell, Fiona Considerations for vaccinating children against COVID-19 |
title | Considerations for vaccinating children against COVID-19 |
title_full | Considerations for vaccinating children against COVID-19 |
title_fullStr | Considerations for vaccinating children against COVID-19 |
title_full_unstemmed | Considerations for vaccinating children against COVID-19 |
title_short | Considerations for vaccinating children against COVID-19 |
title_sort | considerations for vaccinating children against covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373744/ https://www.ncbi.nlm.nih.gov/pubmed/37487674 http://dx.doi.org/10.1136/bmjpo-2023-001964 |
work_keys_str_mv | AT hartjohnd considerationsforvaccinatingchildrenagainstcovid19 AT ongdarrensuryawijaya considerationsforvaccinatingchildrenagainstcovid19 AT chokephaibulkitkulkanya considerationsforvaccinatingchildrenagainstcovid19 AT onglimannat considerationsforvaccinatingchildrenagainstcovid19 AT veretiilisapeci considerationsforvaccinatingchildrenagainstcovid19 AT crawfordnigelw considerationsforvaccinatingchildrenagainstcovid19 AT russellfiona considerationsforvaccinatingchildrenagainstcovid19 |